Effectiveness and safety of bromocriptine when it is combined with metformin in Indian patients with type II diabetes mellitus

Effectiveness and safety of add on therapy of bromocriptine with metformin in Indian patients with type II diabetes mellitus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/05/002659

Enrollment

Registered

2012-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Moderate cases of type II diabetes mellitus Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Bromocriptine: Tab Bromocriptine (0.8 mg) 1 tab once daily for 3 months Intervention2: Bromocriptine: Tab bromocriptine (1.6 mg) 1 tab once daily for 3 months Control Intervention1: Met

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 18 yrs 2. Diagnosed cases with type 2 diabetes mellitus 3. HbA1C >= 6.5 &

Exclusion criteria

Exclusion criteria: 1. Female patients who are pregnant or lactatin 2. FPG 250mg/dl, PPPG 350mg/dl 3. Co-morbid cardiovascular, renal and psychatric complications 4. Co-administration of drugs that are likely to interact with bromocriptine or metformin

Design outcomes

Primary

Measure	Time frame
HbA1CTimepoint: 12 week visit	—

Secondary

Measure	Time frame
Fasting and post prandial plasma glucoseTimepoint: 4, 8 and 12 week visit	—

Countries

India

Contacts

Public ContactArijit Ghosh

Assistant Professor Dept of Pharmacology

drarijitghosh@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026